These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35019268)

  • 1. Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers.
    Yu H; Palazzolo JS; Zhou J; Hu Y; Niego B; Pan S; Ju Y; Wang TY; Lin Z; Hagemeyer CE; Caruso F
    ACS Appl Mater Interfaces; 2022 Jan; 14(3):3740-3751. PubMed ID: 35019268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
    Chen HA; Ma YH; Hsu TY; Chen JP
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphenol-Functionalized Cubosomes as Thrombolytic Drug Carriers.
    Yu H; Palazzolo JS; Ju Y; Niego B; Pan S; Hagemeyer CE; Caruso F
    Adv Healthc Mater; 2022 Nov; 11(21):e2201151. PubMed ID: 36037807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
    Xu J; Zhang Y; Xu J; Liu G; Di C; Zhao X; Li X; Li Y; Pang N; Yang C; Li Y; Li B; Lu Z; Wang M; Dai K; Yan R; Li S; Nie G
    Adv Mater; 2020 Jan; 32(4):e1905145. PubMed ID: 31788896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug delivery under cover of erythrocytes extends drug half-life: A thrombolytic targeting therapy utilizing microenvironment-responsive artificial polysaccharide microvesicles.
    Shan L; Wang J; Tu H; Zhang W; Li H; Slezak P; Lu F; Lee D; Hu E; Geng Z; Lan G; Xie R
    Carbohydr Polym; 2024 Nov; 343():122505. PubMed ID: 39174110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent.
    Chang LH; Chuang EY; Cheng TM; Lin C; Shih CM; Wu AT; Jheng PR; Lu HY; Shih CC; Mi FL
    Acta Biomater; 2021 Oct; 134():686-701. PubMed ID: 34358695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
    Absar S; Nahar K; Kwon YM; Ahsan F
    Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteria-propelled microtubular motors for efficient penetration and targeting delivery of thrombolytic agents.
    Xie S; Mo C; Cao W; Xie S; Li S; Zhang Z; Li X
    Acta Biomater; 2022 Apr; 142():49-59. PubMed ID: 35158079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
    Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
    Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.
    Bonnard T; Tennant Z; Niego B; Kanojia R; Alt K; Jagdale S; Law LS; Rigby S; Medcalf RL; Peter K; Hagemeyer CE
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development a novel nano-platform for Thrombolysis acceleration by Thrombin sensitive polymer-peptide hybrid nancapsules.
    Farnoudian-Habibi A; Aliebrahimi S; Sehati F; Nabavizadeh F; Asadi H; Montazeri V; van Nostrum CF; Rad-Malekshahi M; Nasser Ostad S
    Int J Pharm; 2024 Sep; 663():124561. PubMed ID: 39111356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
    Ma H; Jiang Z; Xu J; Liu J; Guo ZN
    Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocyte-Derived Nanoparticles as a Theranostic Agent for Near-Infrared Fluorescence Imaging and Thrombolysis of Blood Clots.
    Vankayala R; Corber SR; Mac JT; Rao MP; Shafie M; Anvari B
    Macromol Biosci; 2018 Apr; 18(4):e1700379. PubMed ID: 29479820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
    Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
    Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.
    Hua X; Zhou L; Liu P; He Y; Tan K; Chen Q; Gao Y; Gao Y
    J Thromb Thrombolysis; 2014 Jul; 38(1):57-64. PubMed ID: 24671732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.
    Boulaftali Y; Lamrani L; Rouzaud MC; Loyau S; Jandrot-Perrus M; Bouton MC; Ho-Tin-Noé B
    Thromb Haemost; 2012 May; 107(5):962-71. PubMed ID: 22552380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.